Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. develops RNA-targeted medicines and reports news around marketed medicines and a pipeline in neurology, cardiometabolic disease and other high-need areas. Company updates commonly address commercial performance for TRYNGOLZA, financial results, R&D revenue from partnerships, and progress across antisense oligonucleotide programs.
Clinical and regulatory news also covers programs such as olezarsen for severe hypertriglyceridemia, zilganersen for Alexander disease, and partner-developed bepirovirsen for chronic hepatitis B. Governance and investor-relations releases include annual meeting materials, board composition changes, and healthcare conference presentations.
Ionis (Nasdaq: IONS) said the FDA accepted the New Drug Application for zilganersen for Alexander disease and granted Priority Review with a PDUFA target date of September 22, 2026. The pivotal study showed a 33.3% least-square-mean gait-speed improvement (10MWT) at week 61 (p=0.0412) with favorable safety. Zilganersen previously received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations. New pivotal-study data will be presented at the 2026 AAN annual meeting.
Ionis (Nasdaq: IONS) announced board changes effective June 4, 2026: B. Lynne Parshall and Joseph Wender will retire at term end, and Peter N. Reikes will rejoin the board.
Parshall and Wender are long-tenured directors; Reikes returns with recent roles at ARPA-H and the FDA and extensive healthcare finance experience.
Ionis (Nasdaq: IONS) will present new data supporting DAWNZERA (donidalorsen) for hereditary angioedema (HAE) at the 2026 AAAAI Annual Meeting in Philadelphia. Presentations include new analyses from the Phase 3 OASIS-HAE and OASISplus studies and one-year adolescent results.
Ionis will present eight poster presentations on Feb 27 and Mar 1, 2026, covering switching benefit, adherence, safety and efficacy in adolescents, patient-reported outcomes, predictors of disease control, unmet needs, and severity assessment.
Ionis (Nasdaq: IONS) announced the FDA has accepted the sNDA for olezarsen in severe hypertriglyceridemia (sHTG) and granted Priority Review, with a PDUFA target action date of June 30, 2026. The filing is supported by Phase 3 CORE and CORE2 results.
In those studies, olezarsen showed up to a 72% placebo-adjusted triglyceride reduction, an 85% reduction in acute pancreatitis events, and nearly 90% of treated patients reached triglycerides <500 mg/dL; safety and tolerability were described as favorable.
Ionis (Nasdaq: IONS) reported 2025 total revenue of $944 million (up from $705M in 2024), driven by commercial launches and a $280 million sapablursen upfront. TRYNGOLZA first-year net sales were $108 million. Cash and short-term investments were $2.7 billion at year-end.
2026 guidance: $800–$825M revenue, non-GAAP operating loss $500–$550M, and cash ~$1.6B.
Ionis (Nasdaq: IONS) said management will appear at six investor conferences in late February and March 2026, offering fireside chats and webcasts.
Dates include Feb 26, Mar 2, Mar 9, Mar 11 and Mar 17, 2026, with live webcasts and replays available on the company's investor website and archived for a limited time.
Ionis (NASDAQ: IONS) changed the start time for its fourth quarter and full year 2025 financial results webcast to 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. The date of the call is unchanged and a replay will be available for a limited time at the company's investor events page.
Ionis (Nasdaq: IONS) will host a live webcast on Wednesday, February 25, 2026 at 11:30 a.m. Eastern Time to discuss fourth quarter and full year 2025 financial results and to highlight progress on key programs. A replay will be available for a limited time on the investor events page.
Ionis (Nasdaq: IONS) and Otsuka announced that the European Commission approved DAWNZERA (donidalorsen) for routine prevention of hereditary angioedema (HAE) in adults and adolescents 12+ in the EU.
Approval follows positive Phase 3 OASIS-HAE and OASISplus data, including a 94% overall mean monthly attack rate reduction at one year in the OASISplus open-label extension. DAWNZERA is self-administered by subcutaneous autoinjector every four or eight weeks. Ionis is eligible for a $15 million milestone payment and tiered royalties up to 30% on net sales; Otsuka holds exclusive rights in Europe and Asia Pacific.
Ionis (Nasdaq: IONS) reported 2025 momentum and set 2026 catalysts including two planned independent launches and multiple Phase 3 readouts. TRYNGOLZA (olezarsen) generated preliminary U.S. net product sales of $105M in 2025 and a U.S. sNDA for severe hypertriglyceridemia was submitted; peak annual TRYNGOLZA net sales guidance was raised to >$2 billion. Positive pivotal Phase 3 topline results were announced for bepirovirsen in chronic hepatitis B with planned global regulatory submissions in 2026. Ionis expects a total of five Phase 3 readouts and four NDA/sNDA submissions in 2026, plus launches for DAWNZERA, olezarsen (sHTG) and zilganersen (Alexander disease), and targets cash flow breakeven in 2028.